PSMA — Drug Target

All drugs that target PSMA — marketed and clinical-stage. Includes 5 drug classes acting on this target.

Drug classes

Radioactive Diagnostic Agent [EPC] · Radioligand Therapeutic Agent [EPC] · Radiopharmaceutical · Radiolabeled peptide · Radioligand

Marketed (2)

• PIFLUFOLASTAT · Radioactive Diagnostic Agent [EPC]
  Piflufolastat F 18 binds to PSMA-expressing cells, including prostate cancer cells, and emits positrons for imaging.
• LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN · Radioligand Therapeutic Agent [EPC]
  Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death.

Phase 3 pipeline (3)

• [68Ga]CBP8 PET/MRI · Brigham and Women's Hospital · Radiopharmaceutical · Oncology
  This drug is a radiopharmaceutical that targets the PSMA protein.
• rhPSMA-7.3 (18F) Injection · Blue Earth Diagnostics · Radiopharmaceutical · Oncology
  rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging.
• [18F]PSMA-PET · Region Västerbotten · Oncology
  binds to prostate-specific membrane antigen (PSMA) to visualize prostate cancer

Phase 2 pipeline (2)

• 177Lu-DOTA-TLX591 · Telix Pharmaceuticals (Innovations) Pty Limited · Radiolabeled peptide · Oncology
  177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.
• 99m-TC-PSMA-I&S · IRCCS San Raffaele · Radiopharmaceutical · Oncology
  99m-TC-PSMA-I&S is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging of prostate cancer.

Phase 1 pipeline (1)

• 67Cu-SAR-bisPSMA · Clarity Pharmaceuticals Ltd · Radioligand · Oncology
  PSMA-targeting radioligand